This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dantzig, A. H. Articles by Starling, J. J. Search for Related Content PubMed PubMed Citation Articles by Dantzig, A. H. Articles by Starling, J. J.

Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Potent Cyclopropyldibenzosuberane Modulator, LY335979

Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285-0424

Overexpression of P-glycoprotein (Pgp) by tumors results in multidrug resistance (MDR) to structurally unrelated oncolytics. MDR cells may be sensitized to these oncolytics when treated with a Pgp modulator. The present study evaluates LY335979 as a modulator both in vitro and in vivo. LY335979 (0.1 µM) fully restored sensitivity to vinblastine, doxorubicin (Dox), etoposide, and Taxol in CEM/VLB₁₀₀ cells. Ly335979 modulated Dox cytotoxicity even when LY335979 (0.5 µM) was removed 24 h prior to the cytotoxicity assay. LY335979 blocked [³H]azidopine photoaffinity labeling of the M_r 170,000 Pgp in CEM/VLB₁₀₀ plasma membranes and competitively inhibited equilibrium binding of [³H]vinblastine to Pgp (K_i of 0.06 µM). Treatment of mice bearing P388/ADR murine leukemia cells with LY335979 in combination with Dox or etoposide gave a significant increase in life span with no apparent alteration of pharmacokinetics. LY335979 also enhanced the antitumor activity of Taxol in a MDR human non-small cell lung carcinoma nude mouse xenograft model. Thus, LY335979 is an extremely potent, efficacious modulator that apparently lacks pharmacokinetic interactions with coadministered anticancer drugs and is, therefore, an exciting new agent for clinical evaluation for reversal of Pgp-associated MDR.

¹ To whom requests for reprints should be addressed. Phone: (317) 276-5083; Fax: (317) 276-9086.

Received 2/26/96. Accepted 7/16/96.

This article has been cited by other articles:

				M. F. De Rosa, C. Ackerley, B. Wang, S. Ito, D. M. Clarke, and C. Lingwood Inhibition of Multidrug Resistance by AdamantylGb3, a Globotriaosylceramide Analog J. Biol. Chem., February 22, 2008; 283(8): 4501 - 4511. [Abstract] [Full Text] [PDF]

				N. Shaik, N. Giri, G. Pan, and W. F. Elmquist P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution Drug Metab. Dispos., November 1, 2007; 35(11): 2076 - 2085. [Abstract] [Full Text] [PDF]

				N. A. de Vries, J. Zhao, E. Kroon, T. Buckle, J. H. Beijnen, and O. van Tellingen P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan Clin. Cancer Res., November 1, 2007; 13(21): 6440 - 6449. [Abstract] [Full Text] [PDF]

				A. Kaddoumi, S.-U. Choi, L. Kinman, D. Whittington, C.-C. Tsai, R. J.Y. Ho, B. D. Anderson, and J. D. Unadkat Inhibition of P-glycoprotein Activity at the Primate Blood-Brain Barrier Increases the Distribution of Nelfinavir into the Brain but Not into the Cerebrospinal Fluid Drug Metab. Dispos., September 1, 2007; 35(9): 1459 - 1462. [Abstract] [Full Text] [PDF]

				T. Yamagata, H. Kusuhara, M. Morishita, K. Takayama, H. Benameur, and Y. Sugiyama Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients Drug Metab. Dispos., July 1, 2007; 35(7): 1142 - 1148. [Abstract] [Full Text] [PDF]

				J. M. Perez-Victoria, F. Cortes-Selva, A. Parodi-Talice, B. I. Bavchvarov, F. J. Perez-Victoria, F. Munoz-Martinez, M. Maitrejean, M. P. Costi, D. Barron, A. Di Pietro, et al. Combination of Suboptimal Doses of Inhibitors Targeting Different Domains of LtrMDR1 Efficiently Overcomes Resistance of Leishmania spp. to Miltefosine by Inhibiting Drug Efflux. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3102 - 3110. [Abstract] [Full Text] [PDF]

				A. Pichler, N. Zelcer, J. L. Prior, A. J. Kuil, and D. Piwnica-Worms In vivo RNA Interference-Mediated Ablation of MDR1 P-Glycoprotein Clin. Cancer Res., June 15, 2005; 11(12): 4487 - 4494. [Abstract] [Full Text] [PDF]

				V. Sharma, J. L. Prior, M. G. Belinsky, G. D. Kruh, and D. Piwnica-Worms Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood-Brain Barrier J. Nucl. Med., February 1, 2005; 46(2): 354 - 364. [Abstract] [Full Text] [PDF]

				P. M. Fracasso, L. J. Goldstein, D. P. de Alwis, J. S. Rader, M. A. Arquette, S. A. Goodner, L. P. Wright, C. L. Fears, R. J. Gazak, V. A. M. Andre, et al. Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies Clin. Cancer Res., November 1, 2004; 10(21): 7220 - 7228. [Abstract] [Full Text] [PDF]

				D. Peer, Y. Dekel, D. Melikhov, and R. Margalit Fluoxetine Inhibits Multidrug Resistance Extrusion Pumps and Enhances Responses to Chemotherapy in Syngeneic and in Human Xenograft Mouse Tumor Models Cancer Res., October 15, 2004; 64(20): 7562 - 7569. [Abstract] [Full Text] [PDF]

				F. Munoz-Martinez, P. Lu, F. Cortes-Selva, J. M. Perez-Victoria, I. A. Jimenez, A. G. Ravelo, F. J. Sharom, F. Gamarro, and S. Castanys Celastraceae Sesquiterpenes as a New Class of Modulators That Bind Specifically to Human P-Glycoprotein and Reverse Cellular Multidrug Resistance Cancer Res., October 1, 2004; 64(19): 7130 - 7138. [Abstract] [Full Text] [PDF]

				A. Sandler, M. Gordon, D. P. de Alwis, I. Pouliquen, L. Green, P. Marder, A. Chaudhary, K. Fife, L. Battiato, C. Sweeney, et al. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy Clin. Cancer Res., May 15, 2004; 10(10): 3265 - 3272. [Abstract] [Full Text] [PDF]

				S. U. C. Sankatsing, J. H. Beijnen, A. H. Schinkel, J. M. A. Lange, and J. M. Prins P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1073 - 1081. [Full Text] [PDF]

				J. Kankesan, A. Yusuf, E. Laconi, R. Vanama, G. Bradley, J. J. Thiessen, V. Ling, P. M. Rao, S. Rajalakshmi, and D. S. R. Sarma Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats Carcinogenesis, December 1, 2003; 24(12): 1977 - 1984. [Abstract] [Full Text] [PDF]

				F. Van Bambeke, J.-M. Michot, and P. M. Tulkens Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics J. Antimicrob. Chemother., May 1, 2003; 51(5): 1067 - 1077. [Full Text] [PDF]

				R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]

				E. H. Rubin, D. P. de Alwis, I. Pouliquen, L. Green, P. Marder, Y. Lin, R. Musanti, S. L. Grospe, S. L. Smith, D. L. Toppmeyer, et al. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies Clin. Cancer Res., December 1, 2002; 8(12): 3710 - 3717. [Abstract] [Full Text] [PDF]

				C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview Oncologist, December 1, 2002; 7(6): 516 - 530. [Abstract] [Full Text] [PDF]

				S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. G. Schuetz, L.-B. Lan, K. Yasuda, R. L. Shepard, M. A. Winter, J. D. Schuetz, et al. Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-Glycoprotein Mol. Pharmacol., May 1, 2002; 61(5): 964 - 973. [Abstract] [Full Text] [PDF]

				S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. G. Schuetz, L.-B. Lan, K. Yasuda, R. L. Shepard, M. a Winter, J. D. Schuetz, et al. Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates Mol. Pharmacol., May 1, 2002; 61(5): 974 - 981. [Abstract] [Full Text] [PDF]

				S. H. Jang, M. G. Wientjes, and J. L.-S. Au Kinetics of P-Glycoprotein-Mediated Efflux of Paclitaxel J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1236 - 1242. [Abstract] [Full Text] [PDF]

				H. Sun, P. M. Bungay, and W. F. Elmquist Effect of Capillary Efflux Transport Inhibition on the Determination of Probe Recovery During in Vivo Microdialysis in the Brain J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 991 - 1000. [Abstract] [Full Text]

				Q. Mi, B. Cui, G. L. Silva, D. Lantvit, E. Lim, H. Chai, M. You, M. G. Hollingshead, J. G. Mayo, A. D. Kinghorn, et al. Pervilleine A, a Novel Tropane Alkaloid that Reverses the Multidrug-resistance Phenotype Cancer Res., May 1, 2001; 61(10): 4030 - 4037. [Abstract] [Full Text]

				J. M. Baron, L. B. Goh, D. Yao, C. R. Wolf, and T. Friedberg Modulation of P450 CYP3A4-Dependent Metabolism by P-glycoprotein: Implications for P450 Phenotyping J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 351 - 358. [Abstract] [Full Text]

				C. J. Kemp, S. Sun, and K. E. Gurley p53 Induction and Apoptosis in Response to Radio- and Chemotherapy in Vivo Is Tumor-Type-dependent Cancer Res., January 1, 2001; 61(1): 327 - 332. [Abstract] [Full Text]

				P. Mistry, A. J. Stewart, W. Dangerfield, S. Okiji, C. Liddle, D. Bootle, J. A. Plumb, D. Templeton, and P. Charlton In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576 Cancer Res., January 1, 2001; 61(2): 749 - 758. [Abstract] [Full Text]

				W. F. Symmans, M. D. Volm, R. L. Shapiro, A. B. Perkins, A. Y. Kim, S. Demaria, H. T. Yee, H. McMullen, R. Oratz, P. Klein, et al. Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment Clin. Cancer Res., December 1, 2000; 6(12): 4610 - 4617. [Abstract] [Full Text]

				A. Stewart, J. Steiner, G. Mellows, B. Laguda, D. Norris, and P. Bevan Phase I Trial of XR9576 in Healthy Volunteers Demonstrates Modulation of P-glycoprotein in CD56+ Lymphocytes after Oral and Intravenous Administration Clin. Cancer Res., November 1, 2000; 6(11): 4186 - 4191. [Abstract] [Full Text] [PDF]

				H. A. Bardelmeijer, J. H. Beijnen, K. R. Brouwer, H. Rosing, W. J. Nooijen, J. H. M. Schellens, and O. van Tellingen Increased Oral Bioavailability of Paclitaxel by GF120918 in Mice through Selective Modulation of P-glycoprotein Clin. Cancer Res., November 1, 2000; 6(11): 4416 - 4421. [Abstract] [Full Text] [PDF]

				E. F. Choo, B. Leake, C. Wandel, H. Imamura, A. J. J. Wood, G. R. Wilkinson, and R. B. Kim Pharmacological Inhibition of P-glycoprotein Transport Enhances the Distribution of HIV-1 Protease Inhibitors into Brain and Testes Drug Metab. Dispos., June 1, 2000; 28(6): 655 - 660. [Abstract] [Full Text]

				M. J. Newman, J. C. Rodarte, K. D. Benbatoul, S. J. Romano, C. Zhang, S. Krane, E. J. Moran, R. T. Uyeda, R. Dixon, E. S. Guns, et al. Discovery and Characterization of OC144-093, a Novel Inhibitor of P-Glycoprotein-mediated Multidrug Resistance Cancer Res., June 1, 2000; 60(11): 2964 - 2972. [Abstract] [Full Text] [PDF]

				T. Cantz, A. T. Nies, M. Brom, A. F. Hofmann, and D. Keppler MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells Am J Physiol Gastrointest Liver Physiol, April 1, 2000; 278(4): G522 - G531. [Abstract] [Full Text] [PDF]

				A. H. Dantzig, R. L. Shepard, K. L. Law, L. Tabas, S. Pratt, J. S. Gillespie, S. N. Binkley, M. T. Kuhfeld, J. J. Starling, and S. A. Wrighton Selectivity of the Multidrug Resistance Modulator, LY335979, for P-Glycoprotein and Effect on Cytochrome P-450 Activities J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 854 - 862. [Abstract] [Full Text]

				Y. Cui, J. König, U. Buchholz, H. Spring, I. Leier, and D. Keppler Drug Resistance and ATP-Dependent Conjugate Transport Mediated by the Apical Multidrug Resistance Protein, MRP2, Permanently Expressed in Human and Canine Cells Mol. Pharmacol., May 1, 1999; 55(5): 929 - 937. [Abstract] [Full Text]

				G. D. Luker, K. R. Nilsson, D. F. Covey, and D. Piwnica-Worms Multidrug Resistance (MDR1) P-glycoprotein Enhances Esterification of Plasma Membrane Cholesterol J. Biol. Chem., March 12, 1999; 274(11): 6979 - 6991. [Abstract] [Full Text] [PDF]

				M. C. Cabot, A. E. Giuliano, T.-Y. Han, and Y.-Y. Liu SDZ PSC 833, the Cyclosporine A Analogue and Multidrug Resistance Modulator, Activates Ceramide Synthesis and Increases Vinblastine Sensitivity in Drug-sensitive and Drug-resistant Cancer Cells Cancer Res., February 1, 1999; 59(4): 880 - 885. [Abstract] [Full Text] [PDF]

				W. J. Ehlhardt, J. M. Woodland, T. M. Baughman, M. Vandenbranden, S. A. Wrighton, J. S. Kroin, B. H. Norman, and S. R. Maple Liquid Chromatography/Nuclear Magnetic Resonance Spectroscopy and Liquid Chromatography/Mass Spectrometry Identification of Novel Metabolites of the Multidrug Resistance Modulator LY335979 in Rat Bile and Human Liver Microsomal Incubations Drug Metab. Dispos., January 1, 1998; 26(1): 42 - 51. [Abstract] [Full Text]

				G. D. Luker, T. P. Flagg, Q. Sha, K. E. Luker, C. M. Pica, C. G. Nichols, and D. Piwnica-Worms MDR1 P-glycoprotein Reduces Influx of Substrates without Affecting Membrane Potential J. Biol. Chem., December 21, 2001; 276(52): 49053 - 49060. [Abstract] [Full Text] [PDF]